Pfizer Long Term Debt 1986-2025 | PFE

Pfizer long term debt from 1986 to 2025. Long term debt can be defined as the sum of all long term debt fields.
  • Pfizer long term debt for the quarter ending June 30, 2025 was $57.502B, a 0.01% decline year-over-year.
  • Pfizer long term debt for 2024 was $57.405B, a 6.72% decline from 2023.
  • Pfizer long term debt for 2023 was $61.538B, a 87.14% increase from 2022.
  • Pfizer long term debt for 2022 was $32.884B, a 9.15% decline from 2021.
Pfizer Annual Long Term Debt
(Millions of US $)
2024 $57,405
2023 $61,538
2022 $32,884
2021 $36,195
2020 $37,133
2019 $35,955
2018 $32,909
2017 $33,538
2016 $31,398
2015 $28,740
2014 $31,541
2013 $30,462
2012 $31,036
2011 $34,926
2010 $38,410
2009 $43,193
2008 $7,963
2007 $7,314
2006 $5,546
2005 $6,347
2004 $7,279
2003 $5,755
2002 $3,140
2001 $2,609
2000 $1,123
1999 $525
1998 $527
1997 $729
1996 $687
1995 $833
1994 $604
1993 $571
1992 $571
1991 $397
1990 $193
1989 $191
1988 $227
1987 $249
1986 $285
1985 $324
Pfizer Quarterly Long Term Debt
(Millions of US $)
2025-06-30 $57,502
2025-03-31 $57,639
2024-12-31 $57,405
2024-09-30 $58,002
2024-06-30 $57,506
2024-03-31 $61,307
2023-12-31 $61,538
2023-09-30 $61,048
2023-06-30 $61,356
2023-03-31 $31,704
2022-12-31 $32,884
2022-09-30 $32,629
2022-06-30 $34,294
2022-03-31 $35,656
2021-12-31 $36,195
2021-09-30 $36,250
2021-06-30 $35,354
2021-03-31 $35,347
2020-12-31 $37,133
2020-09-30 $49,785
2020-06-30 $50,529
2020-03-31 $36,281
2019-12-31 $35,955
2019-09-30 $36,044
2019-06-30 $36,168
2019-03-31 $35,733
2018-12-31 $32,909
2018-09-30 $33,652
2018-06-30 $28,935
2018-03-31 $31,831
2017-12-31 $33,538
2017-09-30 $34,503
2017-06-30 $34,191
2017-03-31 $36,330
2016-12-31 $31,398
2016-09-30 $30,437
2016-06-30 $30,457
2016-03-31 $27,824
2015-12-31 $28,740
2015-09-30 $29,079
2015-06-30 $26,729
2015-03-31 $29,370
2014-12-31 $31,541
2014-09-30 $31,666
2014-06-30 $32,267
2014-03-31 $27,649
2013-12-31 $30,462
2013-09-30 $31,812
2013-06-30 $31,532
2013-03-31 $31,481
2012-12-31 $31,036
2012-09-30 $31,083
2012-06-30 $30,868
2012-03-31 $33,543
2011-12-31 $34,926
2011-09-30 $35,399
2011-06-30 $35,723
2011-03-31 $35,308
2010-12-31 $38,410
2010-09-30 $39,010
2010-06-30 $37,765
2010-03-31 $38,281
2009-12-31 $43,193
2009-09-30 $32,402
2009-06-30 $31,864
2009-03-31 $21,064
2008-12-31 $7,963
2008-09-30 $7,152
2008-06-30 $7,246
2008-03-31 $8,143
2007-12-31 $7,314
2007-09-30 $6,041
2007-06-30 $5,777
2007-03-31 $4,771
2006-12-31 $5,546
2006-09-30 $5,561
2006-06-30 $5,450
2006-03-31 $6,508
2005-12-31 $6,347
2005-09-30 $5,414
2005-06-30 $5,517
2005-03-31 $6,432
2004-12-31 $7,279
2004-09-30 $7,956
2004-06-30 $6,765
2004-03-31 $7,144
2003-12-31 $5,755
2003-09-30 $6,439
2003-06-30 $6,710
2003-03-31 $3,713
2002-12-31 $3,140
2002-09-30 $3,118
2002-06-30 $3,072
2002-03-31 $2,580
2001-12-31 $2,609
2001-09-30 $2,087
2001-06-30 $2,367
2001-03-31 $1,888
2000-12-31 $1,123
2000-09-30 $1,257
2000-06-30 $1,266
2000-03-31 $524
1999-12-31 $525
1999-09-30 $525
1999-06-30 $530
1999-03-31 $525
1998-12-31 $527
1998-09-30 $528
1998-06-30 $724
1998-03-31 $729
1997-12-31 $729
1997-09-30 $729
1997-06-30 $731
1997-03-31 $732
1996-12-31 $687
1996-09-30 $553
1996-06-30 $583
1996-03-31 $584
1995-12-31 $833
1995-09-30 $358
1995-06-30 $611
1995-03-31 $610
1994-12-31 $604
1994-09-30 $586
1994-06-30 $570
1994-03-31 $570
1993-12-31 $571
1993-09-30 $573
1993-06-30 $574
1993-03-31 $574
1992-12-31 $571
1992-09-30 $592
1992-06-30 $581
1992-03-31 $580
1991-12-31 $397
1991-09-30 $149
1991-06-30 $157
1991-03-31 $177
1990-12-31 $193
1990-09-30 $190
1990-06-30 $182
1990-03-31 $190
1989-12-31 $191
1989-09-30 $207
1989-06-30 $214
1989-03-31 $221
1988-12-31 $227
1988-09-30 $232
1988-06-30 $245
1988-03-31 $330
1987-12-31 $249
1987-09-30 $252
1987-06-30 $273
1987-03-31 $280
1986-12-31 $285
1985-12-31 $324
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $201.199B $100.330B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12